Immunolocalization of BRCA1 protein in tumor breast tissue: Prescreening of BRCA1 mutation in Tunisian patients with hereditary breast cancer?

European Journal of Histochemistry

Volumn 51, Issue 3, 2007, Pages 219-226

  Troudi, Wafa ^a,b,f   Uhrhammer, N ^c   Ben Romdhane, K ^b   Sibille, C ^d   Mahfoudh, W ^e   Chouchane, L ^e   Ben Ayed, F ^b   Bignon, Y J ^c   Ben Ammar Elgaaied, A ^a  

^a FACULTÉ DES SCIENCES DE TUNIS   (Tunisia)

^b SALAH AZAIEZ INSTITUTE   (Tunisia)

^c CENTRE JEAN PERRIN   (France)

^d UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^e UNIVERSITY OF MONASTIR   (Tunisia)

^f UNIVERSITY OF TUNIS EL MANAR   (Tunisia)

Author keywords

BRCA1; BRCA2; Breast cancer; DHPLC; Immunohistochemistry; Sequencing; Tunisian population

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; BRCA1 PROTEIN, HUMAN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CANCER SCREENING; CLINICAL ARTICLE; CONTROLLED STUDY; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; MALE; TUMOR SUPPRESSOR GENE; TUNISIA; BIOSYNTHESIS; BREAST TUMOR; CYTOPLASM; GENETICS; METABOLISM; PAGET NIPPLE DISEASE; PEDIGREE;

BRCA1 PROTEIN; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CARCINOMA, DUCTAL, BREAST; CYTOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PEDIGREE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR SUPPRESSOR PROTEIN P53; TUNISIA;

EID: 35748929094     PISSN: 1121760X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Abbott DW, Thompson ME, Robinson-Benion C, et al. BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair. J Biol Chem 1999; 274:18808-12.
2. Al-Mulla F, Abdulrahman M, Varadharaj G, et al. BRCA1 gene expression in breast cancer: A correlative study between real time RT-PCR and immunohistochemistry. J Histochem Cytochem 2005; 53:621-9.
3. Arnold N, Peper H, Bandick K, et al. Establishing a control population to screen for the occurrence of nineteen unclassified variants in the BRCA1 gene by denaturing high-performance liquid chromatography. Journal of Chromatography B 2002; 782: 99-104.
4. Bernard-Gallon DJ, Crespin NC, Maurizis JC, et al. Cross-reaction between antibodies raised against the last 20 C-terminal amino acids of BRCA1 (C-20) and human EGF and EGF-R in MCF 10a human mammary epithelial cell line. Int J Cancer 1997; 71:123-6.
5. Brose MS, Rebbeck TR, Calzone KA. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002; 94:1365-72.
6. Chen Y, Chen C-F, Riley DJ, et al. Aberrant subcellular localization of BRCA1 in breast cancer. Science 1995; 270:789-91.
7. Coene E, Van-Oostveldt P, Willems K, et al. BRCA1 is localized in cytoplasmic tube-like invaginations in the nucleus. Nat Genet 1997; 16:122-124.
8. Frankish H. BRCA1 has a pivotal role in repairing DNA. Lancet 2001; 357:1678.
9. Jensen RA, Thompson ME, Jetton TL, et al. BRCA1 is secreted and exhibit properties of a granin. Nat Genet 1996; 12:303-8.
10. Kashima K, Oite T, Aoki Y, et al. Screening of BRCA1 mutation using immunohistochemical staining with C-terminal antibodies in familial ovarian cancers. Jpn J Cancer Res 2000; 91:399-409.
11. Kennedy RD, Quinn JE, Johnston PG, et al. BRCA1: mechanisms of inactivation and implications for managements of patients. The Lancet 2002;360:1007-14.
12. Koonin EV, Altschul SF and Bork P. BRCA1 protein products. Functional motifs. Nat. Genet. 1996;13:266-268.
13. Miki Y, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266, 66-71.
14. Nathanson KL, et al. Breast cancer genetics: What we know and what we need. Nat Med. 2001; 7:552-6.
15. Oefner and Underhill PA. DNA mutation detection using denaturing high performance liquid chromatography (DHPLC). In "Current Protocols in Human Genetics," 1997; (N.C.Dracopoli, J.Haines, B.R. Korf, C. Morton, C.E. Seidman, J.G. Seidman, D.T. Moir, and D.R. Smith, Eds.), Suppl.19, pp.7.10.1-7.10.12, Wiley, New York.
16. Page DL, Anderson TJ, Elston CX. Grading of invasive carcinoma of the breast. In Page DL and Anderson TJ eds. Diagnostic histopathology of the breast. New York: Churchill Livingstone 1987; 300-11.
17. Rodriguez JA, Henderson BR. Identification of a functional nuclear export signal in BRCA1. J. Biol Chem 2000;275:38589-96.
18. Scully R, Ganesan S, Brown M, et al. Location of BRCA1 in human breast and ovarian cancer cells. Science (Washington DC) 1996;272: 123-6.
19. Scully R, Chen J, Plug A, et al. Association of BRCA1 with Rad51 in Mitotic and Meiotic Cells. Cell 1997;88: 265-75.
20. Thompson D, Easton DF. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002; 94:1358-65.
21. Wilson CA, Payton MN, Pekar SK, et al. BRCA1 protein products: antibody specificity. Nat. Genet 1996;13: 264-5.
22. Wooster R, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378:789-92.
23. Yoshikawa K, Honda K, Inamoto T, et al. Reduction of BRCA1 Protein Expression in Japanese Sporadic Breast Carcinomas and Its Frequent Loss in BRCA1-associated Cases. Clinical Cancer Research 1999; 5:1249-61.
24. Zhong Q, Chen CF, Li S, et al. Association of BRCA1 with the hRAD50-hMRE11-p95 complex and the DNA damage response. Science 1999;285:747-50.